Hyalubrix syringe 30mg/2ml

Hyalubrix 30mg/2ml syringe is a sterile viscoelastic solution, designed for the treatment of joints affected by degenerative or mechanical arthropathy. Produced by Fidia Farmaceutici , this injectable solution contains hyaluronic acid sodium salt, obtained by bacterial fermentation, which is distinguished by its high molecular weight. Hyaluronic acid is a natural component of synovial fluid, essential for maintaining the viscosity and elasticity necessary for lubrication and cushioning of joints.

In pathological conditions, such as trauma or joint degeneration, the amount of hyaluronic acid decreases, compromising joint function and causing pain. Hyalubrix injection helps restore the viscoelastic properties of synovial fluid, reducing pain and improving joint function for up to six months. It is particularly indicated for the treatment of persistent pain in patients who do not respond adequately to analgesics or nonsteroidal anti-inflammatory drugs.

Hyalubrix 30mg/2ml syringe is ideal for joint infiltrations in various joints, including the knee, hip, shoulder, ankle and trapeziometacarpal joint. This medical device offers an effective solution to improve joint mobility and protect joints from mechanical damage, contributing to a better quality of life for those suffering from osteoarthritis and other joint conditions.

Dosage and method of use

How do I use Hyalubrix syringe 30mg/2ml?

The injection must be strictly intra-articular. Intra-articular injection must be performed according to the standard technique, using precise anatomical localization. In the hip, shoulder and other less easily accessible joints, ultrasound or radioscopic guidance is recommended. All rules regarding asepsis and injection techniques must be observed. Remove any joint effusions, if present, before administration. Inject HYALUBRIX using a suitable sterile needle (e.g. 18 or 20 G), into the affected joint at weekly intervals for 3 weeks. If necessary, further courses of injections may be performed, although systematic collection of clinical data is not available. Clinical data demonstrate the efficacy of HYALUBRIX for up to 6 months, however if clinically required the administration course may be repeated starting 3 months after the first treatment course.

Ingredients Hyalubrix syringe 30mg/2ml

What ingredients does Hyalubrix 30mg/2ml syringe contain?

Hyaluronic acid sodium salt 1.5%, sodium chloride, dibasic sodium phosphate 12H ₂ O, monobasic sodium phosphate 2H ₂ O, water for injections.

Warnings

What are the warnings of Hyalubrix syringe 30mg/2ml?

Do not administer to patients with known individual sensitivity to the components of the product. Do not administer in case of infections or skin diseases in the area of ​​injection. Do not administer to patients with active synovitis. The safety and efficacy of HYALUBRIX in pregnant women, breastfeeding women or in subjects under 18 years of age have not been established and therefore its use is contraindicated in these patient populations. Do not use if the package is damaged. Do not use the product after the expiry date shown on the package. The expiry date refers to the product stored in its original packaging. The syringe is for single use, which means that it is to be used only once and on a single patient. Inject the contents into a single joint. For the first 24 hours after the injection, the patient is allowed to continue all routine activities of daily life, but it is recommended not to overload the treated joint. The syringe complete with needle must be discarded immediately after use, even if the solution has not been completely administered. If the product is reworked and/or reused, Fidia Farmaceutici cannot guarantee its performance, functionality, material structure, cleanliness or sterility. Reuse may lead to illness, infection and/or harm to the patient or user. After use, dispose of in accordance with current regulations. Keep out of reach of children. Localized pain, swelling, heat and redness may occasionally occur at the injection site. These symptoms are generally mild and transient. After intra-articular injection, applying an ice pack to the treated joint for five to ten minutes will reduce the incidence of these events. Local or systemic allergic reactions may occur in subjects with hypersensitivity to the components of the product. More marked inflammatory reactions, sometimes with the presence of sodium pyrophosphate crystals, have occasionally been reported in conjunction with intra-articular injections of hyaluronate. As with any intra-articular treatment, septic arthritis may rarely occur if general precautions for injections are not observed or the injection site is not aseptic. Do not use in conjunction with disinfectants containing quaternary ammonium salts, since hyaluronic acid may precipitate in their presence. Avoid the simultaneous administration of HYALUBRIX with other products for intra-articular use, in order to prevent any possible interaction.

Hyalubrix syringe format 30mg/2ml

Case containing 1 pre-filled syringe. The syringe is sealed in a blister sterilized by ethylene oxide and contains 30 mg of hyaluronic acid sodium salt in 2 ml of steam sterilized solution.